The greatest risk factor for nearly every major cause of mortality in developing nations is aging (1) . In studies on aging, the primary objective is to improve the quality of life, not necessarily with the goal of extending life for a much longer period, but by combating disease. Some notable ways for doing such are discussed in a recent article and include: reversing genome damage caused by aging, diet, and environmental factors; researching new tissue and blood; restricting caloric intake; and reprogramming senescent cells (2) . Rapamycin, an immunosuppressive drug, has been shown to extend life in mice. Studies on resveratrol in cell cultures and in animals have shown that it protects against inflammation, oxidative stress, and cancer and it seemingly extended the life span of worms (3) . Senescent cells are cells that are programmed to stop dividing if they are in danger of becoming cancerous but are active to stimulate regeneration and repair. While they no longer divide, they continue to secrete signaling molecules as inflammation causing factors. Groups of senescent cells can produce such high levels of these chemicals that other normal cells turn senescent. This secreted cocktail can activate a variety of age-related pathologies including heart disease and some types of cancer. A common feature of senescent cells is the accumulation of abnormal or damaged proteins in their cytosol that impairs cellular function. Protein accumulation results in part from impaired protein degradation with age (4). Most of the proteins that are responsible for different diseases and ageing need to be identified. Therapeutic approaches are developed to target and reprogram these cells and to deactivate them.
IS THERE A ROLE FOR THERAPEUTIC APHERESIS IN THE REMOVAL OF SUCH ABNORMAL OR DAMAGED PROTEINS?
Therapeutic apheresis is the removal and/or modifications of blood substances as plasma solutes and blood cells in various disease states to effect a positive change in the disease state. Various technologies have been described in the literature including plasma and whole blood exchange and plasma treatment, for example, by solute-binding sorbents and membranes. Akin to therapeutic apheresis, the process of parabiosis has been investigated. In parabiosis studies, the circulation systems of old and young species are shared such as by plasma exchange (5) . In some studies, old mice have showed signs of rejuvenation while younger mice have showed signs of aging. The general hypothesis is that young molecules help repair damage and detoxify old mice. Very interestingly, it has been shown that using parabiosis with blood exchange between old and young mice that new brain cells form in the hippocampus of young mice with young blood, but when young mice received old blood, brain cell formation slows demonstrating that old blood in mice contains substances that can cause health decline (6) . However, the researchers point out that the results have been difficult to interpret and the exchange involves other processes such as oxygenation and filtration that can lead to a misinterpretation of results. The work by Irina and Michael Conboy found that the effects of young and old blood transfusions on the mice were complex (7). Old mice were better able to recover from muscle tissue injury when given young blood, but the young blood did not improve neuron regeneration in the old mice. Neuron and liver cell regeneration were inhibited in young mice that received blood from elderly animals implying old blood contains substances that cause health decline. They go on to state that identifying the substances and figuring out ways to remove them from old blood may be a more successful approach to thwarting the aging process than a dose of young blood (7) .
The research on senescent cells is particularly interesting as it shows that the body, by design, is programmed to account for changes in aging and address some causes of diseases that are more prevalent with aging. As noted, senescent cells accumulate abnormal proteins that impair cellular function. With age, protein accumulation results in impaired protein degradation as misfolding. Misfolding of proteins leads to their non-function, aggregation, and accumulation (8) . Many diseases progress through protein aggregation (Parkinson's, Alzheimer's, Huntington's, ALS and others). Human cells intentionally collect aggregates to prevent other cellular damage (8) and these aggregates can spill over into the plasma. As one approaches the questions on aging and causes of diseases, are there ways to slow down these processes and improve the quality of life? The example of the treatment of Alzheimer's disease can be considered.
REMOVE THE "BAD" AND/OR REPLACE WITH THE "GOOD"?
Two clinical trials in Alzheimer's patients have aimed to administer plasma from young donors (to test the hypothesis that young molecules are important) or replace plasma with albumin (to test the hypothesis that toxic molecules are present). The Stanford University/Alkahest Plasma for Alzheimer SymptoM Amelioration (PLASMA) trial is a randomized, double-blind, placebo-controlled, crossover trial of intravenously administered plasma, 1 unit weekly for 4 weeks, from young donors for treatment of mild-to-moderate Alzheimer's disease (9) . This trial was initiated in 2015 and enrolled 18 patients. As reported in November 2017, the safety, tolerability, and feasibility of administering infusions of blood plasma was shown and early success was noted based on caregivers' reports. The researchers noted that larger numbers of participants would be necessary before conclusions about efficacy could be reached. The Grifols trial is the multicenter, randomized, controlled study to evaluate the safety of short-term plasma exchange followed by long-term plasmapheresis with infusion of human albumin combined with intravenous immunoglobulin in patients with mildto-moderate Alzheimer's disease also referred to as the Alzheimer Management By Albumin Replacement (AMBAR) trial (10) . The purpose of this study is to evaluate changes in cognitive, functional, behavioral, and global domains on the different applicable psychometric batteries and scales following plasma exchange with albumin replacement (Phase 2) or with immunoglobulin replacement (Phase 3). The rationale for the trial is that amyloidbeta peptides are bound to albumin and circulate in the plasma; their removal from the plasma may flush them from the brain. In this trial, 364 subjects with probable mild to moderate Alzheimer's disease were enrolled into three treatment groups and a control group. Interim results reported by Antonio Páez at the American Society for Apheresis annual meeting in May 2016 noted that treatment is feasible with an acceptable adverse event profile and that the main outcome measures show promising improvement/worsening rates (global). Boada et al. (11) reported on the Phase II study in 42 patients assigned to either plasma exchange with albumin or control (sham) groups. Treated patients received a maximum of 18 plasma exchanges. Cerebrospinal fluid amyloid-beta peptide levels after the last plasma exchange were marginally higher in the plasma-exchange treated group versus controls while the plasma amyloid-beta levels were lower in the plasma exchange treated group after each treatment. Patients treated with plasma exchange reportedly showed improvement in memory and language functions which persisted after plasma exchange was discontinued. Cuberas-Borros et al. reported on investigations of the structural and functional brain changes in plasma exchange-treated Alzheimer's disease patients as part of this Phase II clinical trial (12) . Patients received between 3 and 18 plasma exchanges with albumin or sham followed by 6 month follow-up. For 18 treated and 19 controls there was a trend toward decreasing hippocampi and total intracranial volume for both patient groups. After 6 months the plasma exchange treated group had less cerebral perfusion loss than controls in frontal, temporal, and parietal areas and stabilization or absence of progression of perfusion loss in the plasma exchange group until week 21. The first results of Phase III are to be reported in the near future.
WHILE MORE RESULTS MAY BE FORTHCOMING FROM THESE TRIALS IN ALZHEIMER'S DISEASE PATIENTS, A MAJOR QUESTION STILL EXISTS: IS IT MORE IMPORTANT TO REMOVE THE "BAD" MOLECULES OR REPLACE WITH THE "GOOD"? ARE CRYOGLOBULINS ONE OF THE "BAD" MOLECULES?
While such clinical trials in Alzheimer's patients have not been definitive to date, it is worth identifying disease states that are accompanied by the presence of abnormal and aggregating proteins. One such group are disease states associated with cryoproteins. Cryoproteins represent a group of proteins that aggregate and are seen in various disease states including cryoglobulinemias, multiple myeloma and other hematological (lymphoid) malignancies, vasculitis, recurrent glomerular injury and renal diseases, autoimmume diseases, liver diseases, musculoskeletal diseases as rheumatoid arthritis, and various neurological diseases (13) . Cryoproteins spontaneously precipitate and form a gel at low temperatures and resolubilize when the temperature is raised (14) . Cryoprecipitability is related to electrostatic interactions and solubility. Many cryoglobulins are immune complexes. They have been shown to have disease prognostic significance (15) .
These proteins can be found in the plasma as well as tissues and synovial fluid and are frequently seen in older non-healthy persons and as noted in a wide variety of diseases (13, 16, 17) . Cryoimmunoglobulins are not significantly different from their noncryoprecipating counterparts. Some differences in amino acid sequences may exist impacting structure, electrostatic and hydrophobic forces that are important to cryoprecipitability and alterations in their macromolecular structure. Carbohydrate anomalies as sialic acid-related and lipid variations may be associated with complement proteins and antibodies, fibronectin, etc. (18) (19) (20) .
CAN THERAPEUTIC APHERESIS SUPPORT OUR BIOLOGY TO IMPROVE LONGEVITY OR DECREASE MORBIDITY AND MORTALITY?
In a review of various immunologic and metabolic diseases (21, 22) , over 100 diseases of varying types affecting the major organ systems are associated with abnormal or high concentrations of macromolecular proteins and other chemistries in plasma that would lend themselves to therapeutic apheresis. The rationale for the use of extracorporeal therapies resides in the fact that abnormal chemistries exist in various disease states and these excess solutes and abnormal chemistries can be detrimental to the biological state. The removal of these excess solutes and abnormal chemistries can improve the symptomology of the disease state and possibly reverse the disease course. An historical example of this is treatment of renal failure. The abnormal chemistries include various low molecular weight metabolic toxins, electrolytes, and water. Various removal means have been described to remove these solutes but dialysis has been proven to be the most practical means. Despite imperfect removal, the debate is on-going as to the needed removal range; even still, dialysis can sustain life for many years. Dialysis has molecular size removal limits. Many diseases state (metabolic and immunologic) exhibit abnormalities of higher molecular weight solutes or protein-bound solutes. The identification of the most appropriate and cost-effective separation/removal means is important. It is also critically important that the effectiveness and long term safety of apheresis be tested in randomized clinical trials.
My colleagues and research teams have paid particular attention to the removal of pathogenic plasma solutes by the use of non-biologic semiselective means. In particular, we have applied plasma membrane filtration technologies as cryofiltration, thermofiltration, and non-biologic plasma sorbent perfusion. Plasma exchange is non-selective, requires the use of costly foreign proteins for substitution, and potentially the replacement products are a source of contamination. Membrane plasma filtration is particularly useful as the separation is based on a size differential. It is more selective than plasma exchange and is cost-effective compared to other on-line therapies. It does not depend on replacement plasma products and it can be made more selective by temperature selection as by cryofiltration (23) and thermofiltration (24) for lipid removal. We have identified various diseases containing cryoprecipitable proteins and have successfully treated and reported on them including cryoglobulinemia, cryofibrinogenemia, nephrotic syndromes, vasculitis, myasthenia gravis, lupus nephritis, systemic lupus erythematosus, cold agglutinin hemolytic anemia, dermatomyositis, B-cell lymphoma, and many others including multi-center trials in rheumatoid arthritis. Other researchers have also reported success (25) .
We have shown that cryoprecipitable proteins are suppressive to the immunological system such as inhibiting the blastogenesis of normal mononuclear cells and inhibiting neutrophil phagocytosis in a concentration-dependent manner (26) . Lymphocytes showed increases in proliferation pre-to postcryofiltration to the mitogens phytohemagglutinin, concanavalin A, and pokeweed mitogen showing their prior suppression of both T and B cells. Cryoprecipitable proteins had a suppressive effect on normal lymphocyte proliferation (27, 28) . Patient plasmas with cryoglobulinemia were inhibitory to normal granulocyte chemotaxis (27) . In cryoglobulinemia and rheumatoid arthritis patients treated with cryofiltration, the removal of cryoprecipitable proteins improved cellular functions (27) . In biliary cirrhosis patients treated with plasma perfusion over charcoal and an anion exchange resin there was improved cellular functions (27) and in hypercholesterolemia patients treated by thermofiltration, LDL removal remained lower of an extended period of time (29 Plasma treatment for the removal of macromolecules can produce beneficial effects lasting longer, such as improved cellular functions, than would be expected from their physical removal alone. We refer to this as the X-Effect Hypothesis. The clearing of the "biological smoke", those abnormally high concentration and toxic macromolecules, can activate the biological system to return to normalcy and allow pharmaceutical agents to work more effectively. The normal detoxification processes are lacking in disease states and in aging. "Factors" accumulate leading to pathologic processes, at times in response to the disease processes, and the normal removal processes become deficient and eventually overwhelmed. The uptake of these factors by cells leads to their impairment. Figure 1 outlines the consequences of accumulation of pathological macromolecules. Aggregation of proteins occur with enrichment of other pathological factors. A therapeutic approach can be to remove the degraded and abnormal proteins as by therapeutic apheresis and improve cellular functions and stimulate the biological processes to restore the norm. In therapeutic apheresis one can use early intensive therapy with less frequent maintenance treatments and eventually wean the patient off the treatment as has been shown for some disease states unlike the requirement for life-long treatment as by dialysis for renal failure.
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